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There have been numerous suggestions that Hodgkins disease
(HD) may have an infectious aetiology (Vianna et al, 1971;
Vianna, 1974; Alexander et al, 1991a; Mauch et al, 1993), though
the epidemiological and diagnostic complexity of HD has
hindered a complete understanding. Studies suggesting that the
peak of HD cases in early adulthood HD resembles that of para-
lytic poliomyelitis in the pre-vaccine era (Gutensohn and Cole,
1977) support an aetiological pathway in which HD arises as a rare
outcome of a common infection (Gutensohn and Cole, 1981).
There is now extensive evidence to suggest that the infectious
agent, at least in some cases, is Epstein–Barr virus (EBV) (Weiss
et al, 1989; Wu et al, 1990; Khan et al, 1992; Jarrett, 1993;
Oudejans et al, 1997). However, the ubiquitous distribution of
EBV in the normal population, without accompanying disease
(Miller, 1990), suggests that other factors, possibly of host origin,
contribute to the aetiology of HD.
Immune responses to infectious agent causally associated with
HD may be influenced by inter-individual genetic variations. Cell-
surface heterodimers encoded by the HLA class II (DR, DQ and
DP) loci play a pivotal role in the control of immune responses
through the presentation of peptide antigens to T-cells (Brown et
al, 1988; Germain, 1994; Hammer, 1995). A number of recent
studies have suggested that alleles at the HLA-DPB1 locus, the
most centromeric of the three major HLA class II loci (DR, DQ
and DP), may increase susceptibility and resistance to HD. Thus,
HLA-DPB1*0301 was found to be associated with susceptibility,
and *0201 with resistance to HD (Bodmer et al, 1989; Tonks et al,
1992; Cesbron et al, 1993; Pellegris et al, 1993; Klitz et al, 1994;
Oza et al, 1994).
The diagnostic complexity of HD and the excess of males with
certain HD subtypes (Alexander et al, 1991b; Glaser and Jarrett,
1996) suggests that these two DPB1 alleles (*0301, *0201) may
not be the only ones to contribute to HD susceptibility and resis-
tance. This view is supported by the fact that since DPb1 subunits
are made up of 2–3 polymorphic amino acid residues at each of six
hypervariable regions (HVRs) in exon 2 (Bugawan et al, 1990),
some alleles may have identical residues at certain HVRs, but not
at others. In a previous study we alluded to a relationship between
DPB1 alleles and subtypes of HD (Taylor et al, 1996), but there
were insufficient patients for a detailed analysis. To clarify this we
have now extended the study to include 147 HD patients classified
by subtype, gender and polymorphic amino acid alleles, and
compared them with 183 controls.
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Summary It has been suggested in a number of studies that susceptibility to adult Hodgkin’s disease (HD) is influenced by the HLA class II
region, and specifically by alleles at the HLA-DPB1 locus. Since HD is diagnostically complex, it is not clear whether different HLA-DPB1
alleles confer susceptibility to different HD subtypes. To clarify this we have extended a previous study to type DPB1 alleles in 147 adult HD
patients from a single centre. We have analysed patients with nodular sclerosing (NS), mixed cellularity (MC) or lymphocyte predominant (LP)
HD, and gender in relation to HLA-DPBI type, in comparison with 183 adult controls. The results confirmed previously reported associations
of DPB1*0301 with HD susceptibility (relative risk (RR) = 1.42; 95% confidence interval (CI) 0.86–2.36) and DPB1*0201 with resistance to HD
(RR = 0.49; CI 0.27–0.90). However, analysis by HD subtype and gender showed that *0301-associated susceptibility was confined to
females with HD (RR = 2.46; CI 1.02–5.92), and *0201-associated resistance to females with NS-HD (RR = 0.28; CI 0.10–0.79). Susceptibility
to NS-HD was also associated in females with *1001 (RR = 11.73; CI 1.32–104.36), and resistance with *1101 (RR = 0.08; CI 0.01–0.65). In
contrast, susceptibility to LP-HD was associated in males with *2001 (RR = 32.14; CI 3.17–326.17), and to MC-HD with *3401 (RR = 16.78;
CI 2.84–99.17). Comparison of DPB1-encoded polymorphic amino-acid frequencies in patients and controls showed that susceptibility to MC-
HD was associated with Leucine at position 35 of DPB1 (RR = 8.85; CI 3.04–25.77), Alanine-55 (RR = 15.17; CI 2.00–115.20) and Valine-84
(RR = 15.94; CI 3.55–71.49). In contrast, Glutamic acid 69 was significantly associated with resistance to MC-HD (RR = 0.14; CI 0.03–0.60).
Certain DPB1 alleles and individual DPb1 polymorphic amino acid residues may thus affect susceptibility and resistance to specific HD
subtypes. This may be through their influence on the binding of peptides derived from an HD-associated infectious agent, and the consequent
effect on immune responses to the agent.
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Patients and controls
The patients consisted of 147 unrelated adult UK Caucasians with
HD, aged between 15 and 75 years, from the North West of
England. The series included 118 patients described in a prelimi-
nary report (Taylor et al, 1996) together with a further 29 patients.
The patients all attended a single treatment centre (The Medical
Oncology Clinic, Christie Hospital, Manchester, UK). Further
details of the patients are given in Table 1. The control group
consisted of 183 anonymous healthy adult blood donors, collected
by the National Blood Transfusion Service (NBTS) in Manchester,
UK. This compares with 92 adult controls in our previous study
(Taylor et al, 1996). They were a randomly collected series
consisting of 27.9% males, and 61.2% females. In 10% of cases,
the sex of the donor was not specified by the NBTS for reasons of
confidentiality. Gender analysis was thus confined to the controls
where this information was available. The youngest control
subject was 19 years and the oldest was 67 years, the mean and
median ages being 41.4 and 42 years respectively.
Histopathology
Review of tissue sections from diagnostic biopsies for all 147
patients was carried out in the Department of Histopathology at the
Christie Hospital under the supervision of a cancer pathologist
(MH). Assignment of HD subtype was performed in accordance
with the Rye modification of the Lukes classification system (Lukes
et al, 1966a, 1966b). For the purposes of this study, the HD cases
were classified into nodular sclerosing (NS), mixed cellularity
(MC), lymphocyte-predominant (LP), lymphocyte-depleted (LD)
and unclassified. LP is included as a subtype of HD in this study for
completeness and comparative purposes, even though LP is gener-
ally accepted to be a separate disease entity (Pan et al, 1996).
DPB1 genomic DNA amplification
Genomic DNA was extracted from the whole blood of patients and
controls using established methods, and a 288-bp fragment of
HLA-DPB1 exon 2 was amplified using the polymerase chain
reaction (PCR) primers DPB1-5¢ (GAG AGT GGC GCC TCC GC
TCA T) and DPB1-3¢ (GCC GGC CCA AAG CCC TCA CTC)
using PCR conditions described previously (Taylor et al, 1996).
DPB1 typing with SSO probes
DPB1 typing was carried by the method of Bugawan et al (1990)
as described previously (Taylor et al, 1996) using 24 sequence-
specific oligonucleotide (SSO) probes. DNA samples that could
not be assigned a DPB1 type following SSO hybridization were
further analysed by direct DNA sequencing of PCR products.
Allele assignment
DPB1 alleles were assigned from patterns of SSO probe reactivi-
ties according to the XIth HLA workshop (Tait et al, 1992) and as
detailed in the Report of the HLA Nomenclature Committee
(Marsh, 1996). Polymorphic amino acids encoded by six HVRs
situated in exon 2 were deduced from allele assignments as previ-
ously described (Taylor et al, 1996).
Data analysis
DPB1 allele, phenotype and genotype frequencies in the patients
and controls were computed, and results of phenotype frequency
analysis compared by c2 and Fisher’s exact tests. Phenotype rela-
tive risks (RR) were calculated using the method of Sheehe (1966)
and 95% confidence intervals (95% CI) of RRs calculated by the
Mantel and Haentzel (1959) method using the CONTING, 2by2
and ReRi utilities for the IBM-PC provided by Professor Jurg Ott
(Columbia University, NY, USA; see: http://linkage.rockefeller.
edu/soft/linkutil). Significance values for the c2 distribution and
Fisher’s exact test were subjected to the Bonferroni correction by
multiplying P-values by the number of comparisons, unless other-
wise indicated. Differences in DPB1 phenotype distributions in HD
subtype and control groups were determined using the log-likeli-
hood ratio or G-test of Sokal and Rohlf (1981) as described by Klitz
et al (1994). The G-statistic was calculated using a resampling
computer algorithm (rxc. exe) written and provided by Dr George
Carmody (Carleton University, Ottawa, Canada). The algorithm
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Table 1 Diagnostic characteristics and gender of the 147 patients with
Hodgkins disease included in the study
Males Females Total
Diagnostic subtype na %b n % n %
Nodular sclerosing (NS) 47 50.5 43 79.6 90 61.2
Lymphocyte predominant (LP) 19 20.4 3 5.5 22 14.9
Mixed cellularity (MC) 18 19.3 6 11.1 24 16.3
Lymphocyte depleted (LD) 0 0 1 1.8 1 0.6
Unclassified 9 9.6 1 1.8 10 6.8
Total 93 100 54 100 147 100
aNumber (n) of patients within each diagnostic subgroup. bPercentage (%) of
patients in each subgroup.
Table 2 Comparison of HLA-DPB1-typed HD patients (n = 114) with a
larger series of patients (n = 897) from the same specialist centre
Patients Present study  Total group
Number of patients (n)1 1 4 a 897b
Median age (years) 28.9 30.9
Male:Female ratio 1.59:1c 1.73:1
Total survival 105 (92.1)d 694 (77.4)
Histopathology
Nodular sclerosing 76 (66.7)e 467 (52.1)
Lymphocyte predominant 15 (13.2) 140 (15.6)
Mixed cellularity 18 (15.8) 228 (25.4)
Lymphocyte depleted 2 (1.8) 26 (2.9)
Unclassified 3 (2.6) 36 (4)
Staging
Stage I 15 (13.2) 173 (19.3)
Stage II 47 (41.2) 335 (37.3)
Stage III 24 (21.1) 160 (17.8)
Stage IV 28 (24.6) 229 (25.5)
aOf 147 DPB1 typed HD patients, 114 with relevant clinical data were
compared with 897 from the same centre. bData from 897 patients with
Hodgkins disease patients presenting at the Department of Medical
Oncology, Christie Hospital between 1974 and March 1995. cMale:female
ratio for total patient series. dFigures in parentheses are percentage values.was set to simulate 10 000 random distributions in which two
columns (patients and controls) were compared in a 2 ´ N array,
where  N = number of DPB1 phenotypes (rows). DPB1 allelic
diversity (h) was calculated according to the method of Nei and
Roychoudhury (1974) to provide an estimate of expected heterozy-
gosity. This value was compared with the observed heterozygosity
obtained from the frequency of each DPB1 genotype.
RESULTS
Patients
Details of the patients, classified by histological subtype and
gender, are shown in Table 1. Of the 147 patients, 90 (61.2%) were
NS, 22 (14.9%) were LP, 24 (16.3%) were MC, one (0.68%)
patient was LD and ten (6.8%) patients were of unclassifiable
histological subtype. By gender, 50.5% of male patients compared
with 79.6% of female patients were NS, 20.4% of males and 5.5%
females were LP, and 19.3% of males and 11.1% of females were
MC. Overall, male exceeded female patients by 37% (male:female
ratio (M:F) = 1.72:1). The M:F for NS patients was 1.09,
compared with 6.3 and 3.0 for LP and MC patients respectively.
The one LD and ten unclassifiable patients were excluded from the
DPB1 analysis of the non-NS patients, but were included in the
overall analysis. Of the 22 LP patients, nine (40.9%) were classi-
fied as the nodular LP variant, but were not analysed separately
from the other LP cases.
The mean and median ages of the total patient group were 33
years and 30 years respectively. The number of cases was highest
in the 20- to 30-year age group, with an equal number of males and
females in the 20- to 24-year group. Males exceeded females in
most of the other age categories. The 19 male LP and 18 male MC
cases were spread over the age range 15–49. Although a bimodal
age distribution (Glaser and Jarrett, 1996) was not strongly
evident, there was an increase in males > 60 years.
Patient ascertainment
The patient group was a retrospective, hospital-based series
referred for treatment and follow-up to a single centre. Patients
were recruited to the HLA study either at presentation (i.e. before
treatment) or during follow-up (i.e. at varying times after treat-
ment) between 1990 and 1994. Patients presenting before this
period, but lost to follow-up, were not included in the study. The
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Table 3 HLA-DPB1 phenotype frequency in 147 patients with Hodgkin’s disease analysed by histological subtype and gender
DPB1 All Hodgkin’s disease (%) All Male HD (%) Male Female HD (%) Female
allele
Total NS LP MC
control (%)
Total NS LP MC
control (%)
Total NS LP MC
control (%)
*0101 6.1 6.7 4.5 4.2 4.9 6.5 8.5 5.3 0 6.3 5.6 4.7 0 16.7 0
*0201 11.6a 12.2 4.5 12.5 21.3 10.8 12.8 5.3 11.1 16.1 13.0b 11.6c 0 16.7 33.3
*0202 3.4 3.3 0 8.3 1.1 4.3 4.3 0 11.1 1.8 1.9 2.3 0 0 0
*0301 27.2d 28.9 27.3 33.3 20.8 22.6 25.5 21.1 27.8 23.2 35.2e 32.6 66.7 50 17.6
*0401 74.1 68.9 81.8 87.5 69.9 72.0 63.8 78.9 88.9 74.1 77.8 74.4 100 83.3 64.7
*0402 15.6 16.7 22.7 8.3 22.4 17.2 17.0 26.3 11.1 24.1 13.0 16.3 0 0 23.5
*0501 4.8 3.3 9.1 8.3 2.7 4.3 2.1 10.5 5.6 2.7 5.6 4.7 0 16.7 3.9
*0601 3.4 4.4 0 4.2 3.3 2.2 2.1 0 5.6 1.8 5.6 7.0 0 0 7.8
*0901 1.4 2.2 0 0 2.7 2.2 4.3 0 5.6 2.7 0 0 0 0 2.0
*1001 3.4 5.6 0 0 2.2 1.1 2.1 0 0 1.8 7.4 9.3f 00 0
*1101 2.0 0g 0 0 6.0 3.2 0 0 0 6.3 0 0 0 0 3.9
*1301 4.1 5.6 0 4.2 2.2 4.3 6.4 0 5.6 2.7 3.7 4.7 0 0 0
*1401 4.1 3.3 4.5 0 4.9 5.4 4.3 5.3 0 3.6 1.9 2.3 0 0 5.9
*1501 2.0 1.1 4.5 4.2 0.5 2.2 0 5.3 5.6 0.9 1.9 2.3 0 0 0
*1601 1.4 1.1 0 0 2.2 2.2 2.1 0 0 1.8 0 0 0 0 2.0
*1701 1.4 2.2 0 0 2.2 2.2 4.3 0 0 1.8 0 0 0 0 2.0
*1901 0.7 1.1 0 0 0.5 1.1 2.1 0 0 0.9 0 0 0 0 0
*2001 1.4 0 9.1h 0 0 2.2 0 10.5i 0 0 0 000 0
*2601 0 0 0 0 0.5 2.2 0 0 0 0.9 0 0 0 0 0
*2901 0 0 0 0 0.5 2.2 0 0 0 0.9 0 0 0 0 0
*3401 2.0 0 0 4.2 0.5 3.2 0 0 16.7j 0.9 0 0 0 0 0
n = 147 90 22 24 183 93 47 19 18 112 54 43 3 6 51
Footnote DPB1 Statistical comparison Test RR 95% CI Uncorrected Correction Corrected
P-value factor P-value
a *0201 Total HD vs controls c2 0.49 0.27–0.90 0.0191 21 >0.05
b *0201 Female HD vs female controls c2 0.31 0.12–0.80 0.0130 42 >0.05
c *0201 Female NS-HD vs female controls c2 0.28 0.10–0.79 0.0133 126 >0.05
d *0301 Total HD vs controls c2 1.42 0.86–2.36 0.0171 21 >0.05
e *0301 Female HD vs female controls c2 2.46 1.02–5.92 0.0423 42 >0.05
f *1001 Female NS-HD vs female controls Fisher’s 11.73 1.32–104.46 0.0405 252 >0.05
g *1101 NS-HD vs controls Fisher’s 0.08 0.01–0.65 0.0111 126 >0.05
h *2001 LP-HD vs controls Fisher’s 44.76 4.45–449.90 0.0111 126 >0.05
i *2001 Male LP-HD vs male controls Fisher’s 32.14 3.17–326.17 0.0201 252 >0.05
j *3401 Male MC-HD vs male controls Fisher’s 16.78 2.84–99.17 0.0083 252 >0.05
Correction factors were applied to P-values as follows: x21: Number of phenotypes detected; x3: Number of histological subtypes; x2: Gender (male or female);
x2: 2-tailed Fisher’s exact test.minimum time interval from diagnosis to blood sampling was 1
week to 13.5 years (median 1.84 years). To assess the extent to
which patient selection biased the HLA analysis, an HLA-typed
patient group (n = 114) for which there was detailed clinical data
was compared with a total evaluable group of patients (n = 897)
attending the clinic between 1974 and 1995. The total evaluable
group included the DPB1-typed patients.
The two groups are compared in Table 2, which shows that the
distribution of HD subtypes was similar, although the frequency of
NS was slightly greater and MC slightly less in the HLA-typed
group compared with the total group. The M:F ratio of DPB1-
typed patients was less than in the total group, reflecting a deficit
of MC patients. The age and staging of the two groups were not
remarkably different. The overall survival rate of the HLA-typed
patients was 92.1% compared with 77.4% in the total evaluable
group. Comparison of death rates in the total and HLA-typed
groups by Cox regression analysis showed that the typed patients
had a slightly lower death rate than the total group, but this was not
significant (P = 0.23). Given the favourable prognosis of HD in
this centre (Radford et al, 1995), we conclude that any selection
bias of the HLA-typed patients for survival was small.
DPB1 allele and phenotype frequency analysis
HLA-DPB1 typing revealed 19 alleles in the patient series and 20
alleles in the controls. One allele present in the patients was absent
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Table 4 Frequency of DPB1 exon 2 polymorphic amino acids in 147 patients with Hodgkin’s disease in relation to subtype and gender
Amino acid All Hodgkins disease (%) All Male HD (%) Male Female HD (%) Female
Postn. Residue Total NS LP MC
control (%)
Total NS LP MC
control (%)
Total NS LP MC
control (%)
8 Leucine 89.8 86.7 100 95.8 92.3 89.2 83.0 100 100 92.9 90.7 90.7 100 83.3 96.1
8 Valine 49.7 52.2 50.0 45.8 45.9 47.3 48.9 47.4 44.4 49.1 53.7 55.8 66.7 50.0 37.3
9 Phenylalanine 89.8 86.7 100 95.8 92.3 89.2 83.0 100 100 92.9 90.7 90.7 100 83.3 96.1
9 Histidine 10.2 13.3 4.5 0 11.5 10.8 14.9 5.3 0 9.8 9.3 11.6 0 0 9.8
9 Tyrosine 44.2 44.4 45.5 45.8 36.1 40.9 38.3 42.1 44.4 40.2 50.0 51.2 66.7 50.0 27.5
11 Glycine 92.5 90.0 100 100 93.4 91.4 87.2 100 100.0 94.6 94.4 93.0 100 100 96.1
11 Leucine 44.2 47.8 40.9 41.7 41.5 40.9 44.7 36.8 38.9 43.8 50.0 51.2 66.7 50.0 37.3
35 Phenylalanine 98.6 98.9 95.5 100 99.5 98.9 100 94.7 100 99.1 98.1 97.7 100.0 100 100
35 Leucine 10.2 6.7 9.1 29.2a 4.4 11.8 6.4 10.5 33.3b 5.4 7.4 7.0 0 16.7 3.9
35 Tyrosine 14.3 13.3 9.1 12.5 13.7 16.1 14.9 10.5 11.1 16.1 11.1 11.6 0 16.7 3.9
36 Alanine 82.3 77.8 86.4 91.7 76.0 81.7 76.6 84.2 88.9 80.4 83.3 79.1 100 100 66.7
36 Valine 68.7 68.9 68.2 79.2 69.4 67.7 68.1 68.4 77.8 69.6 70.4 69.8 66.7 83.3 72.5
55 Alanine 83.7 77.8 86.4 100c 76.5 83.9 76.6 84.2 100d 81.3 83.3 79.1 100.0 100f 66.7
55 Aspartic acid 61.9 64.4 63.6 58.3 67.2 61.3 66.0 63.2 55.6 67.0 63.0 62.8 66.7 66.7 70.6
55 Glutamic acid 8.8 7.8 9.1 16.7 4.4 9.7 8.5 10.5 16.7 5.4 7.4 7.0 0 16.7 3.9
56 Alanine 86.4 81.1 90.9 100e 78.7 88.2 83.0 89.5 100 83.9 83.3 79.1 100 100 68.6
56 Glutamic acid 61.9 64.4 63.6 58.3 67.2 61.3 66.0 63.2 55.6 67.0 63.0 62.8 66.7 66.7 70.6
57 Aspartic acid 38.1 40.0 40.9 37.5 32.8 36.6 40.4 36.8 33.7 33.0 40.7 39.5 66.7 50.0 33.3
57 Glutamic acid 95.9 93.3 100 100 95.6 95.7 91.5 100 100 95.5 96.3 95.3 100 100 96.1
65 Isoleucine 93.9 94.4 100 91.7 95.6 92.5 93.6 100 88.9 96.4 96.3 95.3 100 100 96.1
65 Leucine 38.8 36.7 45.5 45.8 35.0 36.6 31.9 42.1 44.4 37.5 42.6 41.9 66.7 50.0 33.3
69 Glutamic acid 27.9 34.4 4.5f 29.2 33.9 26.9 36.2 5.3g 33.3 27.7 29.6 32.6 0 16.7 45.1
69 Lysine 95.2 93.3 100 100 93.4 95.7 93.6 100 100 95.5 94.4 93.0 100 100 92.2
69 Arginine 4.1 1.1 4.5 4.2 6.6 5.4 0 5.3 5.6 7.1 1.9 2.3 0 0 3.9
76 Isoleucine 4.8 6.7 0 4.2 2.7 5.4 8.5 0 5.6 3.6 3.7 4.7 0 0 0.0
76 Methionine 91.2 86.7 100 95.8 94.0 91.4 83.0 100.0 100 93.8 90.7 90.7 100 83.3 98.0
76 Valine 38.1 41.1 36.4 33.3 34.4 35.5 40.4 31.6 27.8 37.5 42.6 41.9 66.7 50.0 25.5
84 Aspartic acid 52.4 55.6 45.5 50.0 48.1 49.5 53.2 42.1 44.4 51.8 57.4 58.1 66.7 66.7 39.2
84 Glycine 86.4 85.6 90.9 87.5 89.1 83.9 80.9 89.5 44.4 90.2 90.7 90.7 100 83.3 92.2
84 Valine 4.1 1.1 4.5 16.7h 1.1 5.4 0 5.3 22.2l 1.8 1.9 2.3 0 0 0
85–87 Glu-Ala-Val 52.4 55.6 45.5 50.0 48.1 49.5 53.2 42.1 44.4 51.8 57.4 58.1 66.7 66.7 39.2
85–87 Gly-Pro-Met 87.8 85.6 90.9 95.8 89.6 86.0 80.9 89.5 100 91.1 90.7 90.7 100 83.3 92.2
n = 147 90 22 24 183 93 47 19 18 112 54 43 3 6 51
Footnote Amino acid Statistical comparison RR 95% CI Uncorrected Correction Corrected Corrected
Position Residue
P-value factor P-value Fishers P value
a 35 Leucine MC HD vs. controls 8.85 3.04–25.77 <0.0001 9 0.0001 0.0074
b 35 Leucine Male MC vs. male controls 8.52 2.58–28.16 0.0001 18 0.0026 >0.05
c 55 Alanine MC HD vs. controls 15.17 2.00–115.20 0.0076 9 >0.05 0.0459
d 55 Alanine Male MC vs. male controls 8.69 1.10–68.49 0.0448 18 >0.05 >0.05
e 56 Alanine MC HD vs. controls 13.40 1.76–101.91 0.0121 6 >0.05 >0.05
f 69 Glutamic acid LP HD vs. controls 0.14 0.03–0.60 0.0048 9 0.0435 0.0402
g 69 Glutamic acid Male LP vs. male controls 0.21 0.21–4.77 0.0355 18 >0.05 >0.05
h 84 Valine MC HD vs. controls 15.94 3.55–71.49 <0.0001 9 0.0002 0.0328
i 84 Valine Male MC vs. male controls 13.72 2.97–63.32 0.0001 18 0.0023 >0.05
Correction factors were applied to P values as follows: x2: Gender; x3: Histological subtypes; x2 or x3: Amino acid polymorphism; x2: 2-tailed Fisher’s exact
test.from the controls (*2001), whilst two alleles (*2601, *2901) were
absent from the patients but present in the controls. Analysis of
allelic diversity (h) showed no significant difference in heterozy-
gosity in the total HD group and the controls (data not shown).
The frequency of DPB1 phenotypes in the total patient group and
by subtype was compared with the controls using the 2 ´ N log-
likelihood ratio method to compute the G-statistic. No correction
for the number of DPB1 alleles is required with this method (Klitz
et al, 1994). No significant difference was found in the total patient
series or in each subtype alone (NS, LP and MC) compared with the
controls (data not shown). However, the combined non-NS group
(LP+MC+LD) showed a significant difference from the controls
(G-statistic: 40.3, P = 0.0053), indicating a difference in the
frequency distribution of DPB1 phenotypes due to non-NS-HD.
To identify whether specific DPB1 alleles were associated with
susceptibility and resistance to HD, phenotype relative risks and
95% confidence intervals were determined allele-by-allele in 2 ´ 2
tests for each subtype and gender. The complete results, together
with the statistical analysis, are shown in Table 3. They can be
summarized thus: an excess of females of all HD subtypes typed for
DPB1*0301 (RR = 2.46; 95% CI 1.02–5.92); a deficit of all
patients typed for DPB1*0201 (RR = 0.49; 95% CI 0.27–0.90) and
this was greater in females with NS-HD (RR = 0.28; 95% CI
0.10–0.79); in males, neither *0301 nor *0201 were associated with
susceptibility or resistance respectively. In females, DPB1*1001
was associated with resistance to NS (RR = 11.73; 95% CI
1.32–104.46), and *1101 with resistance to HD (RR = 0.08; 95%
CI 0.01–0.65). In males, *2001 was associated with susceptibility
to LP (RR = 32.14; CI 326.17), and *3401 was associated with
susceptibility to MC (RR = 16.78; 95% CI 2.84–99.17).
Analysis of polymorphic amino acids
DPB1 alleles are composed of combinations of polymorphic DNA
sequences in six HVRs in exon 2 which encode 2–3 polymorphic
amino acids at each position. The identity of these amino acids can
be predicted from the patterns of SSO hybridization used to assign
classical DPB1 alleles. Since none of the HVR sequences is allele-
specific, the same sequence can occur in more than one classical
DPB1 allele. By comparing the frequency of polymorphic amino
acids in patients and controls, corrections need only involve the
number of amino acid alleles at that position. We therefore carried
out a complete analysis in patients and controls of all polymorphic
amino acids encoded at the following positions of DPB1: 8
(Leu/Val), 9 (Phe/His/Tyr), 11 (Gly/Leu), 35 (Phe/Leu/Tyr), 36
(Ala/Val), 55 (Ala/Asp/Glu), 56 (Ala/Glu), 57 (Asp/Glu), 65
(Ile/Leu), 69 (Glu/Lys/Arg), 76 (Ile/Met/Val), 84 (Asp/Gly/Val)
and 85–87 (Glu-Ala-Val/Gly-Pro-Met).
The results are shown in Table 4 in relation to HD subtype and
gender. After correction for the number of comparisons, four
amino acid residues (leucine 35, alanine 55, alanine 56 and valine
84) were significantly associated with susceptibility to HD, and
one (glutamic acid 69) was associated with resistance. Leu 35, Ala
55 and Val 84 were associated with susceptibility in males to MC
(Leu 35: RR = 8.52, 95% CI 2.58–28.16; Ala 35: RR = 8.69,
95% CI 1.10–68.49; Val 84: RR = 13.72, 95% CI 2.97–63.32).
Glutamic acid 69 was associated with resistance to LP (RR = 0.14;
95% CI 0.03–0.60) in males. In contrast to the classical DPB1
phenotype analysis, none of the amino acid comparisons revealed
significant associations with HD in females.
DISCUSSION
A role for the HLA class II region and specifically for alleles at the
HLA-DPB1 locus in the aetiology of Hodgkin’s disease has been
proposed in a number of studies (Bodmer et al, 1989; Tonks et al,
1991, 1992; Klitz et al, 1994; Oza et al, 1994; Taylor et al, 1996).
What has emerged from these studies is that DPB1*0301 appears
to confer susceptibility, and DPB1*0201 resistance to HD.
However, relative risks associated with these alleles were small,
implying either that DPB1 is only a minor contributor to HD
susceptibility, or that they are masked by the diagnostic hetero-
geneity of the disease.
The present study extends our previous work (Taylor et al, 1996)
by the addition of 29 patients and 91 adult controls, using a more
detailed analytical approach. Our results, obtained with patients
from a specific geographical region treated at a single specialist
centre, confirm previous findings of an increase in DPB1*0301 as
an indicator of susceptibility (Tonks et al, 1992) and a decrease in
*0201, indicative of resistance (Bodmer et al, 1989) in HD. They
also show that subclassification of HD by histological subtype and
gender reveal additional associations which were not previously
reported. Our results do not rule out a contribution from other HLA
class II loci (Klitz et al, 1994) and, bearing in mind the greater
incidence of non-NS-HD in males, a role for HLA-associated, X-
linked susceptibility genes.
We found that the increase in DPB1*0301 was greatest in
females with non-NS, and the decrease in DPB1*0201 was
greatest in females with NS. Neither allele appeared to contribute
to susceptibility or resistance to HD in males. Interestingly,
susceptibility in males was associated with two rare alleles *2001
and *3401, and involved LP and MC-HD respectively. We have
previously reported a family with HD in two sisters, both of whom
typed for DPB1*2001 (Gokhale et al, 1995). In females, suscepti-
bility to NS-HD was also associated with DPB1*1001. At first
sight, these results appear to suggest that the HD subtype and the
patient’s gender might influence the DPB1 association. However,
the more likely explanation is that it is a person’s gender and DPB1
type influencing the HD subtype that develops following an aetio-
logical event such as infection with a virus. If this is the case, it
raises the possibility that certain DPB1 alleles may do this by their
influence on the presentation of infection-derived peptides to T-
cells. Precisely how an ensuing immune response to the infectious
agent affects HD pathology remains to be determined. One possi-
bility is that the magnitude or type of T-cell response elicits the
proliferation of a lineage-specific premalignant clone.
The present study was carried out on a hospital-based patient
series which consisted of retrospectively and prospectively ascer-
tained HD patients. We sought to minimize sources of bias by
limiting the study to a single specialist treatment centre with diag-
nostic review by the same cancer pathology department. The
excellent overall survival rate of the Manchester patients (Radford
et al, 1995) suggests that there was only minimal selection bias
favouring survivors. This was confirmed by comparing the
survival of the DPB1-typed patients with a total evaluable patient
group from the same centre. There was no major difference in
overall survival despite a small deficit of MC patients in the DPB1-
typed group. Previous studies of HLA class II alleles in HD
patients (Tonks et al, 1992; Klitz et al, 1994) have also involved
hospital-based patient series.
Although we tested and confirmed a prior hypothesis that
DPB1*0301 was associated with susceptibility and DPB1*0201
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associations was lost when the null hypothesis of no association
was corrected for the number of tests (DPB1 alleles, HD subtype
and gender). This emphasizes one of the problems encountered in
studying the contribution of a highly polymorphic genetic system
to the aetiology of a rare, diagnostically heterogeneous disease,
especially where the genetic contribution may be indirect and of
low penetrance. Even though uncorrected allele associations may
be chance findings, they are of value in calculating the size of the
patient and control groups required to verify such observations.
Since DPb1 peptide diversity is determined by polymorphic
amino acids coded by each of the six DPB1 HVRs (Bugawan et al,
1990) an alternative approach was to analyse their frequency,
instead of analysing classical DPB1 alleles (i.e. *0101, *0201 etc).
Each HVR shows only limited polymorphism, so the magnitude
of the Bonferroni correction at each position is much less than
required when correcting for the number of classical DPB1 alleles.
Furthermore, since the polymorphic amino acids encoded by each
HVR are themselves probably involved in determining antigenic
peptide-binding and disease susceptibility, each polymorphic
position in exon 2 is arguably at least, if not more, important than
classical alleles.
The results of this analysis showed that even after correction for
the number of comparisons (amino acid, subtype and gender),
there were significant associations between specific amino acids
and histological subtypes. Four amino acid residues were found to
be involved in susceptibility to MC-HD, two of which (leucine 35
and valine 84) were significantly increased by virtue of their pres-
ence in rare DPB1 alleles. The increased frequency of leucine 35
in males with MC can be related to its presence in DPB1*0202,
*0501 and *3401, whilst the increase in valine 84 in males with
MC can be attributed to an excess of *1501 and *3401. Alanine
55, which was increased in male MC, occurs in a number of alleles
whose frequency was greater in males with MC (*0401, *0301,
*1501 and *3401) than in male controls. Glutamic acid at position
69 seems to protect males against LP, due to its occurrence in
*0201. Although not significant, there was also a reduced
frequency of glutamic acid 69 in all female subtypes, and was
completely absent (as was *0201) from the three female LP
patients. The allele *2001 occurred in two patients, both of which
were males with LP, but not in controls. This rare allele is closely
related to *0301, with which it differs by coding methionine, not
valine, at position 76. The occurrence of valine 76 in DPB1*0201
suggests that HD susceptibility associated with *0301 and *2001
may not be due to this residue, since *0201 is associated with
resistance to HD.
The elucidation of the three-dimensional structure of the
DRb1*0101 peptide (Brown et al, 1993) has identified regions of
the b1 domain which are critical for anchoring processed antigenic
peptides and for the stabilization of DRB a/b heterodimers. A
comparison of DRb1 with DPb1 amino acid sequences shows 71%
identity, whilst the remainder are highly homologous with respect
to hydrophobicity. It is thus possible that the regions in DPb1
equivalent to those in DRb1 have a similar biological function. By
alignment of DRb1 and DPb1 amino acid sequences, residue 55 of
DPb1 (equivalent to residue 57 of DRb) may be in the P9 pocket,
contributing to the stabilization of DPa/DPb heterodimers by the
formation of a salt bridge with DPa. Other homologies suggest
that Val 84 corresponds to residue 86 of DRb and contributes to
the P1 pocket. Glutamic acid at position 69 corresponds to position
71 of DRb and occurs in pocket 4. This pocket is involved in
controlling antigen-specific T-cell responses (Fu et al, 1995) and is
associated with susceptibility to tuberculoid leprosy (Zerva et al,
1996). A single amino acid change at position 71 of DRb is suffi-
cient to alter the peptide-binding characteristics and susceptibility
to rheumatoid arthritis (Hammer et al, 1995), and clearly shows
the close relationship between peptide binding
and disease susceptibility. Furthermore, DPbglutamic acid 69 is
strongly associated with susceptibility to hard metal lung disease
(Potolicchio et al, 1997).
If HD is caused by a single type of infectious agent (EBV?),
individual DPb1 amino acid residues might influence interactions
between premalignant cells containing the virus and host T-cells.
The outcome of this interaction could then influence HD
pathology during the transition to malignancy. Since EBV is
expressed in Reed–Sternberg cells at higher frequency in MC than
NS-HD, the increased frequency of leucine 35, alanine 55 and
valine 84 in MC could indicate a direct role in interactions with
viral peptides. The gender difference in the amino acid association
could mean that the response to an aetiological agent is modified
by X-linked genes. It is worth noting that the gene for X-linked
lymphoproliferative disease, a disease associated with an inability
to combat EBV infection, maps to Xq25 (Skare et al, 1989). A
variant of the XLP gene, together with HLA-DPb1 polymorphic
amino acids, could perhaps contribute to susceptibility to MC-HD.
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